$599

Novartis and Wave Q3 ’26 Earnings; Hengrui Business Updates; Novo/Lilly DTC Ad Lawsuit; EVP and President of Lilly International to Retire

A series of cardiometabolic-related news items has been observed from Novartis, Wave Life Sciences, Hengrui Pharma, Novo, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here